GSK offers glimpse at positive Phase 3 antibiotic data for urogenital gonorrhea
17 Apr 2024
Phase 3Clinical ResultQualified Infectious Disease Product
Two months after its urogenital gonorrhea antibiotic hit the primary endpoint in a registrational trial, GSK is providing a closer look at results as it gears up for regulatory filings in 2025.
The Phase 3 EAGLE-1 trial compared GSK’s antibiotic with standard-of-care ceftriaxone plus azithromycin in 600 people with uncomplicated urogenital gonorrhea. In the primary endpoint of microbiological response at the test-of-cure visit three to seven days after treatment, gepotidacin achieved a 92.6% success rate versus 91.2% for control, per a Wednesday release. The p-value of the non-inferiority endpoint was not disclosed.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.